Revelation Biosciences, Inc. · NASDAQ:REVB
Revelation Biosciences — Investor Presentation (June 2026)
19 slides from Revelation Biosciences's investor presentation, Jun 1, 2026
Slide 1: Innovative Solutions for Acute and Chronic Disease
Innovative Solutions for Acute and Chronic Disease Corporate Presentation NASDAQ: REVB March 2026 www.revbiosciences.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the w
Slide 3: Our Programs
Our Programs Program* (Indication) Significant Unmet Need Next Clinical Milestone Lead Program • ~50% of all ICU patients develop AKI (20% of all GEM-AKI hospitalized)1 Phase 2/3 Pivotal Study (Acute Kidney Injury) • 3.2 Million Patients • $5.5 Billion Market potential Value-Building • 10% of world
Slide 4: Potential Future Applications Using Gemini
Potential Future Applications Using Gemini Neurodegenerative Diseases • Parkinson's • Alzheimer's Disease Cardiovascular Disease • Myocarditis • Pericarditis Hepatic Disease • Cardiorenal Syndrome • MASH • IgA Nephropathy Renal Disease • Acute Kidney Injury • Chronic Kidney Disease Inflammatory Bowe
Slide 5: Gemini Restores Immunologic Homeostasis Through TLR-4 Agonism
Gemini Restores Immunologic Homeostasis Through TLR-4 Agonism Gemini Benefits Normalized Inflammatory response - lower pro-inflammatory cytokine production, intact anti-inflammatory cytokine production – Not immunosuppressive Restoration of immunocompetence Durable reprogramming observed out t
Slide 6: AKI is a Significant Problem
AKI is a Significant Problem Acute Kidney Injury (AKI) is a sudden loss of kidney function • ~50% of all ICU patients develop AKI (20% of all hospitalized)1 • Severe AKI (stage 3) requires the need for dialysis leading to longer recovery times and higher mortality (>50%) • Predominately driven by by
Slide 7: Gemini Phase 2/3 Pivotal Study to Begin Later this Year
Gemini Phase 2/3 Pivotal Study1,2 to Begin Later this Year Phase 2: • Severe stage 2 or stage 3 acute kidney injury patients not yet on dialysis will be administered Gemini or placebo. • Multiple dosing regimens will be evaluated Adaptation (a seamless transition to Phase 3): • The Safest dosing reg
Slide 8: Experienced Management
Experienced Management Experienced management Successful track record in A history of building Management has broad and scientific team multiple startups and turn- successful commercial experience in financings and arounds including organizations investor relations Extensive product development expe
Slide 9: Financial Overview
Financial Overview Key Financial Summary 12/31/2025 Beneficial Holders Shares % Cash $10,700,331 Management 210,848 8.04 Stockholders Equity $8,860,995 Total 210,848 8.04 Cash Used for Operations $8,269,581 Cash Provided by Financing $12,470894 Cap Table Shares Common Stock 3,908,420 Common Stock Wa
Slide 10: Thank You!
Thank You! For more information, please visit www.revbiosciences.com 10
Slide 11: Supplemental Slides
Supplemental Slides BIOSCIENCES
Slide 12: Gemini Rebalances Cellular Equilibrium, Fostering Healing Processes
Gemini Rebalances Cellular Equilibrium, Fostering Healing Processes Hyperinflammation Immunosuppression • Cellular infiltration • Cellular senescence • Sustained immune response, cytokines • Removal of inflammatory signals • Highly cytotoxic environment • Reduced cellular immune response • Pathogen/
Slide 13: AKI in the US – A Significant Unmet Medical Need
AKI in the US – A Significant Unmet Medical Need Cost Burden4 $21,250 (Current Standard of Care) Total Hospital Admissions1 34,426,650 All-Cause AKI Incidence2 Treatment Price 6,885,330 $10,625 (Target Price = 50% Cost Savings) AKI Stage 2/32 2,341,012 Target Patients3 Annual Market Potential5 468,2
Slide 14: CKD is a Significant Problem
CKD is a Significant Problem • AKI patients have an increased chance of developing Chronic Kidney Disease (CKD) as a direct result of the damage inflicted by AKI 1 • CKD affects 10% of the global population2 • Worsening renal function as a result of increased inflammation can cause serious damage in
Slide 15: Clinical and Preclinical Data
Clinical and Preclinical Data Demonstration of The Potential of Gemini in Target Indications 15
Slide 16: Gemini Corrected Hyperinflammation and Restored Immunocompetence in CKD Patients
Gemini Corrected Hyperinflammation and Restored Immunocompetence in Patients with CKD in PRIME Clinical Study Gemini reduced background cytokine levels relative to placebo1 • Stage 3 or 4 CKD patient peripheral blood mononuclear cells (PBMCs) were collected prior to and 2, 4, and 24 hours post dose
Slide 17: Gemini significantly reduced fibrotic scarring in a rat model of AKI and CKD
Gemini significantly reduced fibrotic scarring in a rat model of AKI and CKD Gemini significantly reduced new collagen deposition1 • The unilateral urinary obstruction (UUO) model is used for studying AKI and CKD • Daily dosing with Gemini significantly reduced renal fibrosis, or scarring, relative
Slide 18: Gemini significantly improved organ function in a rat model of AKI
Gemini significantly improved organ function in a rat model of AKI Pre-treatment with Gemini significantly reduced serum creatinine (A) 1 and neutrophilic infiltration (B) 2 A. B. • The ischemic reperfusion injury (IRI) model is used to study AKI • Dosing Gemini 24 and/or 48 hours prior to IR: o Sig
Slide 19: Cytokine and Cellular Upregulation in Humans Agree with Animal Models
Cytokine and Cellular Upregulation in Humans Agree with Animal Models Cytokine Upregulation in Humans (Phase 1 study data in healthy volunteers) IL1-RA IL-10 NGAL Neutrophil Cytokine Upregulation in Healthy Animals IL1-RA IL-10 NGAL Neutrophil 19
Revelation Biosciences — Investor Presentation (June 2026) on 6ix